pISSN 2234-3806eISSN 2234-3814
Table. 2.
Differences in MV counts among COVID-19 patients with mild, moderate, and severe clinical symptoms
| Biomarker (MV/µL) | Healthy control (N=9) | COVID-19 clinical symptoms | P | ||
|---|---|---|---|---|---|
| Mild (N=30) | Moderate (N=30) | Severe (N=30) | |||
| AnnV+ PMVCD42b+ | 761.4 (414.2–1,294.8) | 1,118.3 (328.1–1,910.5) | 937.4 (311.4–2,909.5) | 1,298.8 (458.2–9,703.5) | 0.009 |
| AnnV+ PMVCD41a+ | 543.9 (395.4–1,055.0) | 885.5 (346.3–1,682.7) | 663.5 (233.8–2,081.5) | 1,146.3 (333.3–10,296.6) | 0.007 |
| AnnV+ MMVCD14+ | 697.4 (357.7–941.0) | 761.1 (164.0–1,416.8) | 711.1 (217.1–2,058.5) | 912.7 (263.8–6,795.8) | 0.063 |
The results are expressed as median (range). Data from mild, moderate, and severe clinical symptoms were analyzed using the Kruskal–Wallis test. Significance was set at P<0.05.
Abbreviations: MV, microvesicle; AnnV+, annexin V-positive; COVID-19, coronavirus disease; PMVCD42b+, CD42b+ platelet MV-positive; PMVCD41a+, CD41a+ platelet MV-positive; MMVCD14+, CD14+ monocyte microvesicle-positive.
Ann Lab Med 2024;44:392~400 https://doi.org/10.3343/alm.2023.0395
© Ann Lab Med